Picard Medical, Inc. and SynCardia Systems LLC CEO to Present at CSI Focus D-HF 2025 in Frankfurt, Germany

Rhea-AI Summary

Picard Medical (NYSE American: PMI) announced that CEO Patrick NJ Schnegelsberg will present data on the fully implantable Emperor Total Artificial Heart (TAH) at the CSI Focus D-HF conference in Frankfurt, Germany.

The conference runs December 5–6, 2025, and the presentation is scheduled for Saturday, December 6, 2025, 13:00–13:45 CET in the Red Room during the Durable Mechanical Circulatory Support session. Picard is parent of SynCardia Systems, maker of the first TAH approved by both the U.S. FDA and Health Canada.

News Market Reaction

+2.02% 149.0x vol

47 alerts

+2.02% News Effect

+98.6% Peak in 31 hr 14 min

+$6M Valuation Impact

$306M Market Cap

149.0x Rel. Volume

On the day this news was published, PMI gained 2.02%, reflecting a moderate positive market reaction. Argus tracked a peak move of +98.6% during that session. Our momentum scanner triggered 47 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $6M to the company's valuation, bringing the market cap to $306M at that time. Trading volume was exceptionally heavy at 149.0x the daily average, suggesting very strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Conference dates: December 5–6, 2025 Presentation date: Saturday, December 6, 2025 Presentation time: 13:00–13:45 CET

3 metrics

Conference dates December 5–6, 2025 CSI Focus D-HF conference schedule

Presentation date Saturday, December 6, 2025 CEO Emperor TAH session timing

Presentation time 13:00–13:45 CET Durable Mechanical Circulatory Support session slot

Market Reality Check

Price: $1.61 Vol: Volume 482,950 is 0.19x t...

low vol

$1.61 Last Close

Volume Volume 482,950 is 0.19x the 20-day average of 2,536,297, indicating subdued trading interest pre-announcement. low

Technical Price $2.47 is below the $2.69 200-day moving average, reflecting weakness versus longer-term trend.

Peers on Argus

PMI was up 3.05% while key medical device peers were flat to down (e.g., KIDS -2...

PMI was up 3.05% while key medical device peers were flat to down (e.g., KIDS -2.96%, LAB -1.33%), suggesting a stock-specific move rather than a sector-wide shift.

Historical Context

5 past events · Latest: Dec 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 09	Clinical durability update	Positive	-8.7%	Reported record <b>2,900 days</b> support with SynCardia Total Artificial Heart.
Dec 03	Conference presentation	Positive	+2.0%	Announced CEO’s Emperor TAH data presentation at CSI Focus D-HF.
Nov 26	Conference data update	Positive	+1.9%	Planned in vitro Emperor TAH data presentation at ISMCS 2025 meeting.
Nov 19	Pre-clinical implantation	Positive	-6.7%	Completed first in vivo Emperor TAH implantations in pre-clinical models.
Nov 14	Earnings and IPO update	Positive	+10.7%	Reported Q3 2025 results, IPO proceeds, and portfolio/patent milestones.

Pattern Detected

Recent positive milestones and updates often led to gains, but there are notable instances where seemingly positive clinical news coincided with short-term declines.

Recent Company History

This announcement fits a stream of updates highlighting Picard’s SynCardia and Emperor Total Artificial Heart platforms. Over the last month, the company reported Q3 2025 results with IPO proceeds and improved losses on Nov 14, followed by first in vivo Emperor TAH implantations on Nov 19 and in vitro data at ISMCS 2025 on Nov 26. Subsequent news featured a CSI Focus D-HF presentation on Dec 3 and a patient achieving 2,900 days of SynCardia support on Dec 9, underscoring ongoing technical progress and visibility efforts.

Market Pulse Summary

This announcement highlights further visibility for Picard’s fully implantable Emperor Total Artific...

Analysis

This announcement highlights further visibility for Picard’s fully implantable Emperor Total Artificial Heart, with the CEO scheduled to present data during a specialized heart-failure session at CSI Focus D-HF. In context of recent in vitro and in vivo Emperor TAH milestones and Q3 2025 financial disclosures, investors may focus on how new data support the platform’s durability and clinical trajectory, while also monitoring financing developments, regulatory updates, and subsequent trial progress for a fuller risk–benefit picture.

Key Terms

total artificial heart, emperor total artificial heart (tah), mechanical circulatory support

3 terms

total artificial heart medical

"maker of the world’s first total artificial heart approved by both the U.S."

A total artificial heart is a surgically implanted mechanical device that replaces the heart’s two main pumping chambers and takes over circulation, acting like a continuous pump that keeps blood moving through the body. Investors care because it is a high-cost, high-stakes medical product whose commercial success depends on clinical trial results, regulatory approvals, hospital adoption, reimbursement rules and long-term patient outcomes — factors that drive revenue potential and risk.

emperor total artificial heart (tah) medical

"present data on the fully implantable Emperor Total Artificial Heart (TAH) at the"

A total artificial heart (TAH) is a mechanical device that replaces a failing human heart, pumping blood throughout the body much like a spare engine replacing a broken one. The Emperor TAH name denotes a specific model of this lifesaving technology; investors watch it because clinical results, regulatory approvals, manufacturing scale and insurance coverage determine whether the device can reach patients and generate revenue for its maker.

mechanical circulatory support medical

"Session: Durable Mechanical Circulatory SupportLocation: Red Room"

Mechanical circulatory support are medical devices that help or take over the heart’s job of moving blood around the body, ranging from temporary external pumps to implanted pumps that assist one or both sides of the heart. For investors, these devices matter because their use drives sales, regulatory scrutiny, reimbursement decisions and long‑term healthcare costs; think of them as a backup engine for a failing heart whose adoption and outcomes influence a company’s market opportunity and risk profile.

AI-generated analysis. Not financial advice.

TUCSON, Ariz., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that Patrick NJ Schnegelsberg, CEO will attend and present data on the fully implantable Emperor Total Artificial Heart (TAH) at the upcoming CSI Focus D-HF (Device Therapies in Heart Failure) conference, scheduled for December 5^th through 6^th, 2025 in Frankfurt, Germany.

Details of the presentation are below:

Date: Saturday, December 6, 2025
Time: 13:00 – 13:45 CET
Session: Durable Mechanical Circulatory Support
Location: Red Room

About CSI Focus D-HF

CSI Focus D-HF (https://www.csi-congress.org/dhf) is the leading global workshop dedicated to device-based therapies for heart failure. It brings together leading interventional cardiologists, engineers, academic researchers, and industry innovators to explore the next generation of heart failure device solutions, including ventricular restoration, neuromodulation, interatrial shunts, implantable monitoring systems, and telemedicine enabled strategies. The conference attracts an international cross-section of experts focused on advancing heart failure device therapies.

About Picard Medical and SynCardia

Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world.

For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.

Contact:

Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com

Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com

General/Media
Brittany Lanza
blanza@syncardia.com

FAQ

When will Picard Medical (PMI) present Emperor TAH data at CSI Focus D-HF 2025?

CEO Patrick NJ Schnegelsberg will present on December 6, 2025, 13:00–13:45 CET in the Red Room.

What topic will Picard Medical (PMI) cover at CSI Focus D-HF 2025?

Presentation of clinical and device data for the fully implantable Emperor Total Artificial Heart (TAH) in the Durable Mechanical Circulatory Support session.

Where is CSI Focus D-HF 2025 and what are the dates?

CSI Focus D-HF 2025 takes place in Frankfurt, Germany from December 5–6, 2025.

Who is presenting Picard Medical (PMI) data at the conference?

Picard Medical CEO Patrick NJ Schnegelsberg will deliver the presentation.

Which session will include the Emperor TAH presentation at CSI Focus D-HF 2025?

The presentation is part of the Durable Mechanical Circulatory Support session in the Red Room.